1: Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala
Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen
Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D;
evolutionRMS investigators. Safety and efficacy of evobrutinib in relapsing
multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre,
randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol. 2024
Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19.
PMID: 39307151.
2: Montalban X, Wallace D, Genovese MC, Tomic D, Parsons-Rich D, Le Bolay C, Kao
AH, Guehring H. Characterisation of the safety profile of evobrutinib in over
1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid
arthritis and systemic lupus erythematosus: an integrated safety analysis. J
Neurol Neurosurg Psychiatry. 2023 Jan;94(1):1-9. doi: 10.1136/jnnp-2022-328799.
Epub 2022 Nov 23. PMID: 36418156; PMCID: PMC9763187.
3: Arnold DL, Elliott C, Martin EC, Hyvert Y, Tomic D, Montalban X. Effect of
Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A
Post Hoc Analysis of a Phase 2 Trial. Neurology. 2024 Mar 12;102(5):e208058.
doi: 10.1212/WNL.0000000000208058. Epub 2024 Feb 9. PMID: 38335474; PMCID:
PMC11067693.
4: Scheible H, Schieferstein H, Schmidt R, Pusecker K, Gradhand U,
Gopalakrishnan S, Iqbal K, Dong J, Jones R, Meli C, Bolleddula J, Dyroff M,
Georgi K. Evobrutinib pathway to its major metabolite M463-2 and insights from a
biotransformation and DDI perspective. Xenobiotica. 2023 Dec;53(8-9):547-558.
doi: 10.1080/00498254.2023.2272180. Epub 2023 Nov 26. PMID: 37880944.
5: van der Walt A. Evobrutinib in multiple sclerosis: challenges and unmet
goals. Lancet Neurol. 2024 Nov;23(11):1068-1070. doi:
10.1016/S1474-4422(24)00391-0. Epub 2024 Sep 19. PMID: 39307153.
6: Papasouliotis O, Mitchell D, Girard P, Dyroff M. Population pharmacokinetic
and pharmacodynamic modeling of evobrutinib in healthy adult participants. Clin
Transl Sci. 2022 Dec;15(12):2899-2908. doi: 10.1111/cts.13417. Epub 2022 Oct 17.
PMID: 36165192; PMCID: PMC9747113.
7: Scheible H, Dyroff M, Seithel-Keuth A, Harrison-Moench E, Mammasse N, Port A,
Bachmann A, Dong J, van Lier JJ, Tracewell W, Mitchell D. Evobrutinib, a
covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route,
and metabolism in healthy participants. Clin Transl Sci. 2021
Nov;14(6):2420-2430. doi: 10.1111/cts.13108. Epub 2021 Aug 10. PMID: 34374206;
PMCID: PMC8604242.
8: Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS,
Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M,
Wolinsky JS. Efficacy and safety results after >3.5 years of treatment with the
Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis:
Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal
fluid sub-study. Mult Scler. 2024 Apr;30(4-5):558-570. doi:
10.1177/13524585241234783. Epub 2024 Mar 4. PMID: 38436271; PMCID: PMC11080380.
9: De Bondt M, Renders J, Petit de Prado P, Berghmans N, Pörtner N, Vanbrabant
L, de Oliveira VLS, Duran G, Baeten P, Broux B, Gouwy M, Matthys P, Hellings N,
Struyf S. Effect on neutrophil migration and antimicrobial functions by the
Bruton's tyrosine kinase inhibitors tolebrutinib, evobrutinib, and fenebrutinib.
J Leukoc Biol. 2025 Mar 14;117(3):qiae160. doi: 10.1093/jleuko/qiae160. PMID:
38976501.
10: Bar-Or A, Cross AH, Cunningham AL, Hyvert Y, Seitzinger A, Gühring H, Drouin
EE, Alexandri N, Tomic D, Montalban X. Antibody response to SARS-CoV-2 vaccines
in patients with relapsing multiple sclerosis treated with evobrutinib: A
Bruton's tyrosine kinase inhibitor. Mult Scler. 2023 Oct;29(11-12):1471-1481.
doi: 10.1177/13524585231192460. Epub 2023 Aug 25. PMID: 37626477; PMCID:
PMC10580670.
